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Strengths and limitations of this study
 ► Recurrent depression is a leading cause of disability 
adjusted life years and antidepressant medication 
(ADM) is the mainstay approach to treatment; this 
study is the first to describe people’s experiences of 
recovery with an ADM alongside a psychosocial ap-
proach designed to support recovery (mindfulness- 
based cognitive therapy (MBCT)).
 ► The sample was relatively large and purposively 
sampled to illustrate a range of recovery journeys 
and outcomes.
 ► Participants experiences in the 2 years following 
MBCT were sampled, using an innovative approach 
to supporting participants’ to describe the richness 
of their experiences of recovery and treatment.
 ► The sampling necessarily meant that we did not in-
clude people with a history of recurrent depression 
who had decided against ADM, tapering and discon-
tinuing their ADM and/or a psychological approach.
AbStrACt
Objectives This study aimed to describe the recovery 
journeys of people with a history of recurrent depression 
who took part in a psychosocial programme designed to 
teach skills to prevent depressive relapse (mindfulness- 
based cognitive therapy (MBCT)), alongside maintenance 
antidepressant medication (ADM).
Design A qualitative study embedded within a 
multicentre, single blind, randomised controlled trial (the 
PREVENT trial).
Setting Primary care urban and rural settings in the UK.
Participants 42 people who participated in the MBCT arm 
of the parent trial were purposively sampled to represent a 
range of recovery journeys.
Interventions MBCT involves eight weekly group 
sessions, with four refresher sessions offered in the year 
following the end of the programme. It was adapted 
to offer bespoke support around ADM tapering and 
discontinuation.
Methods Written feedback and structured in- depth 
interviews were collected in the 2 years after participants 
undertook MBCT. Data were analysed using thematic 
analysis and case studies constructed to illustrate the 
findings.
results People with recurrent depression have unique 
recovery journeys that shape and are shaped by their 
pharmacological and psychological treatment choices. 
Their journeys typically include several over- arching 
themes: (1) beliefs about the causes of depression, both 
biological and psychosocial; (2) personal agency, including 
expectations about their role in recovery and treatment; 
(3) acceptance, both of depression itself and the 
recovery journey; (4) quality of life; (5) experiences and 
perspectives on ADM and ADM tapering- discontinuation; 
and (6) the role of general practitioners, both positive and 
negative.
Conclusions People with recurrent depression describe 
unique, complex recovery journeys shaped by their 
experiences of depression, treatment and interactions 
with health professionals. Understanding how several 
themes coalesce for each individual can both support 
their recovery and treatment choices as well as health 
professionals in providing more accessible, collaborative, 
individualised and empowering care.
trial registration number Clinical trial number 
ISRCTN26666654; post results.
Depression is a major public health problem. 
Globally more than 264 million people suffer 
from depression, and lifetime prevalence 
rates are estimated to be between 6% and 
20%.1 2 Furthermore, depression can be a 
relapsing and recurring condition, and on 
average people who experience one episode 
of depression have seven or eight episodes 
over their lifetime.3 Clinical guidance typi-
cally recommends that people with recurrent 
depression should take maintenance antide-
pressant medications (ADMs) after remis-
sion or engage in preventive psychological 
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interventions to maintain recovery.4 For people with 
recurrent depression, their recovery journey is shaped 
by their experiences of depression, ‘illness model’, inter-
actions with mental health professionals, treatments that 
have and have not worked and expectations about what 
recovery will entail.5 For many, ADMs are an important 
part of their recovery. Reasons for long- term ADM use 
include positive experiences of ADMs, fear of relapse, 
perceived lack of alternatives and concerns about with-
drawal effects.6 On the other hand, people also describe 
a number of reasons for wanting to discontinue ADMs, 
including feeling better and wanting to test whether 
depression has gone away, ambivalence and uncer-
tainty about the role of ADMs in recovery, side effects 
outweighing benefits, questioning whether the self on 
ADMs is the ‘real self’, and wanting to assert control over 
their well- being.7
Research and clinical guidelines suggests that psycho-
logical therapies, such as mindfulness- based cognitive 
therapy (MBCT) and cognitive- behavioural therapy 
(CBT), can support recovery from depression as well as 
support discontinuing ADMs.4 8–10 A significant propor-
tion of people express a preference for psychological ther-
apies, so they can learn strategies that support recovery 
without the need for long- term reliance on ADMs.11 But 
psychological therapies can be difficult to access, involve 
significant investment of time and energy and are not 
effective for everyone.12
While studies have examined people’s experiences of 
ADM and MBCT in recovery, none have focused primarily 
on how they operate alongside one another. This study 
explores how people with a history of recurrent depres-
sion describe their experience of using MBCT and 
ADM to support their recovery, drawing on both written 
feedback booklets and more in- depth interviews. It was 
embedded within a randomised controlled trial (RCT) 
comparing MBCT with support to taper and discontinue 
ADMs (henceforth MBCT- TS) and maintenance antide-
pressants over a 2- year period.13 These findings could 
inform decision- making between general practitioners 
(GPs) and patients about the journey of management 
and recovery from recurrent depression.
MethODS
Study context
This qualitative process evaluation was embedded within 
a randomized controlled trial comparing mindfulness- 
based cognitive therapy with maintenance anti- depressant 
treatment in the prevention of depressive relapse/recur-
rence (the PREVENT trial). This was a multicentre, single 
blind, parallel RCT, which investigated whether MBCT- TS 
(n=212) was superior to maintenance ADMs (n=212) for 
the prevention of depressive relapse or recurrence over 
24 months (trial design is described by Kuyken et al).13–16 
The trial found that MBCT- TS was not superior to main-
tenance ADM in preventing depressive relapse over 
2 years; however, a subsequent individual patient data 
meta- analysis which included this data suggests MBCT as 
an alternative to maintenance ADMs.8 We present a state-
ment concerning reflexivity in the online supplementary 
materials, which outlines the experience and background 
of the authors, to acknowledge our theoretical positions 
and values in relation to this study (see online supple-
mentary 1).17 We also include the consolidated criteria 
for reporting qualitative research (COREQ) checklist to 
match our procedures against standard criteria for quali-
tative research (see online supplementary 2).
Participants
Participants in the PREVENT trial were recruited from 95 
general practices in urban and rural settings in four UK 
centres, in addition to self- referral.13 Inclusion criteria 
were a diagnosis of recurrent major depressive disorder 
in full or partial remission according to the Diagnostic 
and Statistical Manual of Mental Disorders- IV18; three or 
more previous major depressive episodes; age 18 years or 
older; and on a therapeutic dose of maintenance antide-
pressant drugs in line with the British National Formu-
lary and NICE (National Institute for Health and Care 
Excellence) guidance.4 Exclusion criteria were a current 
major depressive episode, comorbid diagnoses of current 
substance misuse; organic brain damage; current or past 
psychosis, including bipolar disorder; persistent antisocial 
behaviour; persistent self- injury needing clinical manage-
ment or therapy; and formal concurrent psychotherapy. 
All participants gave informed consent before partici-
pating in the trial. The full process of recruitment for the 
PREVENT trial is described in Kuyken et al.16
This study examined a sub- group of participants from 
the PREVENT trial (n=42) allocated to the MBCT- TS arm 
of the trial. Of the 212 participants allocated to receive 
MBCT- TS, 176 received an adequate dose of treatment 
(attended four or more group sessions of therapy).13 The 
researchers purposively sampled a sub- group of these 
participants (n=46) to represent a spread of characteristics 
and experiences with respect to: whether they reported 
their childhood as having higher or lower levels of abuse, 
treatment response (relapse/no relapse to a major 
depressive episode), and ADM discontinuation profile 
across the 24- month follow- up period (discontinued 
ADMs, discontinued ADMs but subsequently resumed 
them, tapered ADMs but never fully discontinued, never 
tapered or discontinued ADMs).13 Of the 46 people 
invited to interview, 42 agreed, which comprised the final 
sample. Of the four who declined, two had moved away 
from the area, one was not interested in participating 
and one participant had changed their contact details 
and could not be reached. Interviewees did not differ in 
either baseline characteristics or trial outcomes from the 
broader study sample (see table 1).
MbCt-tS intervention
MBCT- TS comprised MBCT delivered in line with the 
published treatment manual,19 but adapted to include 
a greater focus on developing a relapse/recurrence 
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Table 1 Characteristics of the sample
Interviewed
(n=42)
All MBCT- TS 
participants
(n=212)
Demographic characteristics
  Female (%) 31 (74) 151 (71)
  White (%) 42 (100) 210 (99)
  Age (in years)
  M (SD) 51.88 (10.51) 50 (12)
  Range 25–72 22–78
Psychiatric characteristics
  Previous episodes
  <6 episodes 26 (62) 120 (57)
  ≥6 episodes 16 (38) 92 (43)
  Comorbid mental health 
diagnoses
  1 or more (%) 15 (36) 75 (35)
Treatment preference at 
baseline
  MBCT- TS preference (%) 34 (81) 150 (71)
  ADM preference (%) 1 (2) 12 (6)
  No preference (%) 7 (17) 50 (24)
Treatment outcome
  Relapse
  N (%) that relapsed during 
the follow- up phase
23 (55) 94 (44)
  Antidepressant usage during 
the follow- up phase
  Stopped and stayed stopped 
(%)
13 (31) 67 (32)
  Stopped and resumed (%) 9 (21) 57 (27)
  Reduced but never stopped 
(%)
9 (21) 29 (14)
  Never stopped or reduced 
(%)
11 (26) 23 (11)
  Residual depression 
symptoms
  BDI score at baseline, M (SD) 15.90 (11.35) 13.8 (12.4)
  BDI score at 24- month 
follow- up, M (SD)
12.39 (12.25) 11.6 (10.9)
ADM, antidepressant medication; BDI, Beck Depression Inventory; MBCT- TS, 
mindfulness- based cognitive therapy with support to taper and discontinue 
ADMs.
signature and response plan that explicitly included 
participants’ reduction/discontinuation of ADM (see 
Kuyken et al16 for more detail). The programme involved 
eight 2¼-hour group sessions, normally over consecutive 
weeks, with up to four refresher sessions offered in the year 
following the end of the 8- week programme. Researchers 
encouraged participants in the MBCT- TS arm to taper 
and discontinue their maintenance ADMs at several 
points from the middle of the MBCT- TS course onwards, 
and provided information to GPs and participants about 
typical tapering/discontinuation regimes and possible 
withdrawal effects. If participants experienced a relapse/
recurrence during the course of the trial, researchers 
encouraged them to discuss the most appropriate treat-
ment with their GP and made no further requests that 
they consider tapering/discontinuing their ADMs.
Qualitative data collection
We used both written feedback booklets (collected at two 
time points, soon after MBCT and then at study end) 
and interviews (at study end) to gather participants’ 
more in- depth experiences of recovery. We combined 
each participant’s interview and written feedback booklet 
data to form a single account of their experiences. This 
formed the study’s data corpus.
Written feedback booklets
One month after completing MBCT- TS all trial partic-
ipants were invited to complete a feedback booklet 
addressing attitudes towards, and experiences of, taking 
and reducing antidepressant medication; experiences of 
taking part in MBCT- TS and MBCT- TS practices; and the 
impact of MBCT. In addition to the earlier points, partic-
ipants received a further feedback booklet 24 months 
later, which asked the same questions as the first booklet 
but also included questions focused on participants’ 
experiences in the follow- up period and basic data on the 
amount and type of mindfulness practice. The booklets 
are provided in the online supplementary materials (see 
online supplementary 3 and 4).
Interviews
Interviews were semi- structured and normally conducted 
face- to- face by trained researchers, approximately 24 
months after MBCT- TS. They lasted between 45 min and 
1 hour and explored experiences during the follow- up 
period, with questions addressing times of wellness, early 
signs of potential depressive relapse and relapses. Ques-
tions explored the use and perceived value of mindful-
ness techniques, use of ADMs and their combination. We 
tailored interviews to the specific profile of each partici-
pant using a ‘timeline’ prepared in advance and amended 
by the participant at the interview, which summarised 
each participant’s ADM use, relapses and significant life 
events, as reported to the research team during the trial. 
The interview schedule was deliberately broad in focus 
(see online supplementary 5). Interviews were recorded 
and transcribed for analysis.
Public and patient involvement
The PREVENT trial benefited from the expertise of many 
people with lived experience of mental health difficulties 
including a number of members of a locally organised 
voluntary group called the lived experience group (LEG). 
The LEG assisted the PREVENT trial at every stage of its 
development including both the interview schedule and 
written feedback booklets. There were reviewed and then 
trialled by several members of the LEG who suggested a 
number of fundamental changes. A member of the LEG 
also provided specific training to the research staff on 
conducting interviews.
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Table 2 Themes and sub- themes
Theme Sub- themes
Beliefs about the causes of 
depression
Neurochemical 
disruption
Learning a 
psychological model
Integrating models
Personal agency Control over depression
Responsibility
Acceptance Resolving shame
Self- care
Perspectives on relapse
Quality of life Experiencing emotions 
more fully
From coping to enjoying 
life
ADM tapering/discontinuation Pace of reduction
Managing withdrawal 
effects
Interactions with GP Presence and support
Following advice
ADM, antidepressant medication; GP, general practitioners.
Data analyses
We used thematic analysis as our analytic approach.17 
First, we selected eight participants with a range of 
ADM discontinuation journeys during the trial period: 
two who had discontinued ADMs and remained ADM- 
free; two who had discontinued ADMs and subsequently 
resumed; two who had never tapered or discontinued 
ADMs; and two who had tapered but never discon-
tinued ADMs. Four researchers (AT, CC, JR and WK) 
independently analysed the interview transcripts and 
accompanying 1- month and 24- month feedback book-
lets for each participant. In this phase, we conducted 
inductive analysis, with each researcher developing a 
preliminary coding frame. These frames were then inte-
grated through discussion to remove redundancies and 
ensure breadth. This collaboratively produced, induc-
tive coding frame was then combined with deductive 
codes developed from key literature on participant 
experiences of MBCT,20 21 and ADM use,7 22 to establish 
a working coding frame.
The lead researcher (AT) then analysed the 42 inter-
views and accompanying booklets against this coding 
frame, using NVivo V.11 software. AT, CC and JR met at 
regular intervals to discuss additional emerging codes 
and arising themes and, if deemed appropriate, inte-
grated these into the coding frame. Midway through 
coding, AT sought peer feedback on emerging themes 
from co- authors, at an internal research meeting and 
at a symposium focused on antidepressant tapering at 
an international conference (Tickell, 2018). Feedback 
from these presentations helped clarify which themes 
were particularly important, and in particular helped 
the researchers reflect on those that related specifically 
to participants’ experiences of ADM alongside MBCT- TS. 
Once the data were fully coded, the researchers reviewed 
the themes in the light of the core research question. 
These were discussed with the wider authorship group, 
whose input was used to reduce redundancy across 
themes, and highlight their interactions. Peer review of 
an earlier version of this manuscript also led to further 
refining the questions and themes. Finally, we identified 
cases that illustrated the unique stories of recovery and 
the ways the common themes coalesced in different ways 
in illustrative case studies.
reSultS
The thematic analysis yielded six over- arching themes, 
each with a number of constituent sub- themes. We provide 
a summary (table 2) and narrative account of each theme 
and its constituent sub- themes, illustrating these with 
extracts from participants’ accounts. While each person’s 
experience of MBCT and ADMs was unique, these themes 
converged in complex ways within individual case. Five 
case examples illustrate these different recovery journeys 
(box 1).
beliefs about the causes and treatment of depression
This over- arching theme describes participants’ beliefs 
about the causes of depression and how these beliefs influ-
ence their treatment decisions. This theme comprises 
three sub- themes.
Neurochemical disruption
Many participants described entering the study believing 
that their recurrent depression was due to a neurochem-
ical disruption in their brain, often citing specifically a 
deficiency or imbalance of the neurotransmitter sero-
tonin. Participants viewed medication as a way to correct 
this issue and made parallels to biomedical disorders, 
viewing ADMs as a ‘physiological need’ in the same way 
that ‘diabetics require insulin’ because ‘there is some 
chemical missing’ (2102; Written feedback, Never tapered or 
discontinued). For instance, Annie explained that she went 
on ADMs because her doctor told her that she had lower 
levels of serotonin than other people (see box 1). This 
belief appeared to influence expectations about psycho-
logical therapy, as some participants stated that they 
did not understand how ‘mindfulness would be able to 
counteract depression […] if it’s generated by a chemical 
imbalance’ (1031, Interview, Never tapered or discontinued). 
Other people said that they had not given much thought 
to why they were depressed or how ADMs worked: ‘Happy 
pills […] I've never really given it a great deal of thought 
exactly what they do to be honest. […] I just know I don't 
feel so bad with them’ (2123, Interview, Tapered but never 
discontinued).
Learning a psychological model
Participants described how their views on the causes of 
depression evolved during and following the MBCT- TS 
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box 1 Case examples
Mandy. Mandy, aged 57, experienced nine episodes of depression, be-
ginning when she was 32. Following the mindfulness- based cognitive 
therapy with support to taper and discontinue ADMs (MBCT- TS) course 
Mandy successfully discontinued her antidepressant medication (ADM) 
treatment. She did not experience a relapse over the 24- month follow- 
up period.
Mandy recalled how ADMs had helped her to function well. In the past, 
she had tried tapering, but had always relapsed, so assumed that ADMs 
would be a part of her life forever. At first, Mandy was nervous, but 
was willing to try tapering ADMs gradually and with the support of 
MBCT- TS (Personal Agency: Control Over Depression). Mandy’s GP 
was supportive, but reassured her that it was ultimately her decision 
(Interactions with GP: Presence and Support). During the MBCT- TS 
course, Mandy said that she learned a different model of depression 
and developed a better understanding of ‘how the mind works’ (beliefs 
about the Causes of Depression: learning a Psychological Model). 
She felt more confident about tapering, and said that this time it was 
‘so easy, knowing that I have been given tools to help me through it 
if needed’, and found the course ‘totally liberating’ as it gave her the 
chance to take control of her depression, rather than the other way 
round (Personal Agency: responsibility). She also found it helpful 
to learn about the possible symptoms of withdrawal, which included 
mood swings. Mandy realised that the relapses she had experienced 
when she had tried to taper her ADMs in the past might have been 
withdrawal symptoms, as opposed to ‘real relapses’ (ADM tapering / 
Discontinuation: Managing Withdrawal effects). At the time of inter-
view, having discontinued ADMs, Mandy still practised what she learned 
in MBCT- TS and made it part of her daily routine. She accepted that if 
she ever relapsed, she could use ADMs, but it would only ever be a 
short- term solution, because she has the MBCT- TS skills as a ‘weapon’ 
to help her manage (Acceptance: Self- Care).
Greta. Greta, aged 72, had experienced three episodes of depression, 
beginning when she was 33. Following the MBCT- TS course she discon-
tinued her ADMs but then resumed following a deterioration in mood.
Greta was very optimistic about the course because she hated being on 
ADMs, which gave her unpleasant side effects that interfered with her 
quality of life (Personal Agency: Control over Depression). At first, 
Greta said the course made an ‘immense difference’ to her, and she 
described learning how to combat the negative thoughts and feelings 
she was having (beliefs about the Causes of Depression: learning 
a Psychological Model). The programme left Greta feeling ‘so well 
and positive’ that she decided to taper her ADMs very quickly (ADM 
tapering/Discontinuation: Pace of reduction), but began to feel her 
mood dipping. Greta thought this must be a sign that the programme 
was not working, because she should not feel depressed (Acceptance: 
Perspectives on relapse). Greta went to her GP, who did not seem 
interested in the programme and told her to resume ADMs immediately 
(Interactions with GP: Presence and Support). She was disappointed 
and felt ‘guilty’ that she was not able to use these new skills to keep 
herself well (Personal Agency: responsibility). She stopped practising 
mindfulness, although the programme made her remember to appreci-
ate the high points in her day and experience more joy (Quality of life: 
From Coping to enjoying life).
Annie. Annie, aged 48, had experienced five episodes of depression, 
beginning when she was 23. Following the MBCT- TS programme, she 
discontinued her ADMs but then resumed them later.
Annie felt that ADMs had a positive impact on her life, allowing her to 
cope day- to- day as a full- time carer for her husband who had a disabil-
ity. At first, she was very reluctant to try discontinuing ADMs because 
Continued
box 1 Continued
she believed she might have low levels of serotonin (beliefs about 
the Causes of Depression: Neurochemical Disruption). However, 
the programme taught her a new model of understanding depression 
(beliefs about the Causes of Depression: learning a Psychological 
Model), which made her feel empowered to practice the psychological 
techniques (Personal Agency: responsibility). She started to taper off 
ADMs, but then her mother died and her husband’s health deteriorated, 
so it was difficult to find time to practice mindfulness. Her GP advised 
her it was probably not a good time to discontinue (Interactions with 
GP: Presence and Support), so she resumed ADMs. However, Annie 
still incorporated the mindfulness exercises into her everyday life, 
which brought her more joy (Quality of life: experiencing emotions 
More Fully). She also recognised that it is not her fault when she felt 
depressed, given how challenging her life was (Acceptance: resolving 
Shame). Annie felt that the best way to manage her depression was to 
combine ADMs with mindfulness practices, which gave her more skills 
to look after herself during difficult times (Acceptance: Self- Care). She 
felt hopeful that 1 day she would discontinue ADMs, when her life cir-
cumstances were more stable.
George. George, aged 37, had experienced ten episodes of depression, 
beginning when he was 16. Following the MBCT- TS programme he dis-
continued his ADMs. He experienced a relapse to depression during the 
24- month follow- up.
George was very optimistic about trying an alternative to ADMs, be-
cause they made him feel like a ‘zombie’. Having experienced sub-
stance misuse issues in the past George had the goal of being totally 
‘chemical free’. Before the course, George felt he had no control over 
his depression symptoms, and his mood would deteriorate suddenly 
without warning (Personal Agency: Control). Through practising the 
mindfulness skills, he described developing more awareness of his 
emotions and felt he would have the skills to manage them (Personal 
Agency: responsibility). George said that the best part of taking part in 
MBCT- TS was meeting other people with depression, which made him 
feel more accepting of himself (Acceptance: resolving Shame). He 
felt that ADMs had masked his symptoms, whereas MBCT- TS allowed 
him to explore the problems in his life that were contributing to de-
pression and work through them to make long- term changes (Personal 
Agency: responsibility). When George relapsed shortly after discon-
tinuing ADMs, he carried on practising MBCT- TS and said that the skills 
he learned were enough to pull him out of that period of low mood 
(Acceptance: Perspectives on relapse).
Claire. Claire, aged 49, had experienced four episodes of depression, 
beginning when she was 17. Following the MBCT- TS programme, Claire 
discontinued her ADMs. She relapsed and resumed medication, but 
subsequently tapered and discontinued again, and was not using ADMs 
at the time of her follow- up interview.
At first, Claire was very sceptical about the MBCT- TS programme and 
thought it might all be ‘mumbo jumbo’. However, she was very keen to 
come off ADMs, so she approached the programme with an open mind 
and wanted to give it her all (Personal Agency: Control). As the course 
progressed, Claire changed her mind and began to ‘believe more and 
more that this might help me’. MBCT- TS gave her new ways to cope 
with her feelings, which shocked her because she ‘had never took con-
trol of my depression before’ (Personal Agency: responsibility). She 
became very excited and tapered off her medication ‘too quickly’ and 
‘hit a brick wall in a short amount of time. Went straight back in to a deep 
depression’ (ADM tapering/Discontinuation: Pace of reduction). Her 
doctor was very understanding, and did not push her to do anything, but 
advised her to go back on ADMs and try to taper off again when she was 
Continued
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box 1 Continued
feeling better (Interactions with GP: Presence and Support). He said 
that she should try tapering them more slowly next time even though 
she ‘wanted to get off them as soon as possible’. This time, she did 
‘exactly as she was told’ and did not experience a relapse (Interactions 
with GP: Following Advice). Claire was very pleased because she said 
they had always felt that ADMs had ‘suppressed’ her and that the per-
son she was when taking ADMs ‘wasn’t really me’ (Quality of life: 
experiencing emotions More Fully).
programme. Despite some of the initial reservations 
described earlier, participants described an open mind 
as key to engaging with the new psychological model, in 
which their thoughts, behaviours and emotions played a 
role in depressive relapses and recurrences: ‘in the first 
sessions […] I switched from being highly sceptical to very 
interested very quickly’ (1203, Interview, Discontinued). 
Some participants articulated a move away from ‘treating 
depression as a disease, like if you had a toothache, so 
you took pills’, and were surprised because they ‘hadn’t 
thought that there was an alternative’ (1069, Interview, 
Discontinued). They began to feel confident to discontinue 
ADMs with the support of psychological therapy. In addi-
tion, people described how the programme gave them 
more awareness of how external factors, such as relation-
ships or financial situations, could trigger or exacerbate 
depressive relapses and recurrences. On the other hand, 
some participants found it more difficult to engage in 
the programme and found themselves ‘rebelling against 
it’ because they did not have ‘intellectual confidence in 
the process’ (3105; Written feedback, Never tapered or discon-
tinued). People described how their initial treatment 
experiences influenced their attitudes: those who felt that 
the techniques were helping them to manage depressive 
relapse/recurrence often endorsed the psychological 
model. On the other hand, others who experienced dete-
rioration in mood or relapse sometimes reported that 
they had reconsidered bio- medical explanations, and 
decided to resume or remain on ADMs: ‘I really thought 
depression was a psychosomatic problem, but I am not so 
sure now. I did give it my best shot, using the mindful tech-
niques, but I still fell into the pit of despair […] I feel that 
my depression is caused by a chemical imbalance in my 
body which, at present, is only helped by taking medica-
tion’ (2200; Written feedback, Tapered but never discontinued).
Integrating models
Although some participants viewed depression as either 
biomedical or psychological, many did not see the two 
models as distinct and found ways to integrate them. For 
instance, they conceptualised that ‘antidepressants hold 
onto the chemical in your body ‘cause you’re not making 
enough of it yourself’, while MBCT- TS allows you to ‘focus 
your mind onto how to make your own’ (1139, Interview, 
Never tapered or discontinued). It seemed that participants 
who viewed these models as compatible were more open 
to using ADMs and using psychological techniques as 
an additional way to support their recovery, rather than 
viewing them as competing treatments. Furthermore, 
when participants observed the diversity of other people’s 
experiences on the programme, some formed the opinion 
that there are ‘all sorts of depressions’ underpinned 
by different causes ‘just as there are colds and flu's and 
viruses’ (3105, Interview, Never tapered or discontinued). As 
such, some reasoned that different people would require 
different treatment decisions to support recovery: ‘My 
depression is not necessarily the same as other people’s 
[…] The right combination of changing lifestyle, specific 
therapies, medication whatever else it takes – that seems 
to be different for different people’ (3109, Interview, Never 
tapered or discontinued).
Personal agency
This over- arching theme describes people’s personal 
agency in their recovery and consequently their treat-
ment choices. People described entering the study fearful 
about ADM discontinuation, but were hopeful that a 
psychological programme could support them. During 
MBCT- TS, people spoke about feeling better able to 
manage their vulnerability to depressive relapse, by using 
the skills and techniques they learned on the programme. 
While these enhanced feelings of personal agency were 
largely viewed as a positive and increased many people’s 
confidence to taper and discontinue ADMs, this was not 
always the case. For some having more responsibility to 
manage their condition created a sense of unhelpful pres-
sure. This theme comprises two sub- themes.
Control over depression
People described how their treatment choices affected 
their sense of control over depression. Some felt that 
taking ADMs provided a sense of control, as it kept their 
mood on an even keel. However, this sense of control 
was contingent on taking ADMs, so many participants 
recalled how before the trial they would not consider 
discontinuing because they were afraid that depres-
sion would return. Through MBCT, some participants 
described a change in their sense of personal agency in 
their recovery, describing a shift from being a ‘helpless 
victim of circumstance’, to having more ‘control of my 
feelings and my life’ (1123; Written feedback, Tapered but 
never discontinued). They reported increased awareness 
to recognise the early warning signs of depressive relapse 
and take steps to respond by applying mindfulness or 
cognitive- behavioural techniques from a ‘toolbox’, 
including things like meditation, activity scheduling or 
enlisting social support: ‘Before the trial, I didn’t have the 
tools to recognise what was happening. […] I didn’t even 
know I was getting depressed. [Now] if things are diffi-
cult I can do something about it’ (1203, Interview, Discon-
tinued). Learning these new skills reduced many people’s 
fears about coming off ADMs, because they felt they had 
the capacity to prevent or contain depressive relapses. For 
instance, George said that before the course, he would 
fall into depressive episodes very suddenly and without 
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warning, whereas the skills learned in MBCT- TS gave him 
more awareness and control to act and prevent relapses 
before they occurred (see box 1).
Responsibility
Participants also articulated that learning how they could 
have more agency over their thoughts, feelings, and 
behaviours led to an increased sense of responsibility to 
manage their well- being. Most participants viewed this 
as positive, especially if they were able to use the tech-
niques to manage relapse/recurrence. Some people said 
they preferred MBCT- TS to taking ADMs because it made 
recovery feel more like a personal achievement: ‘Once 
I’ve fallen and I realise that I am depressed, I take myself 
off and say, do 3 or 4 meditations a day. […] Which to me 
is better than taking a pill, because I know I’ve worked 
to get myself well’ (2016, Interview; Written feedback, 
Discontinued).
However, not all participants viewed having more 
agency and responsibility over their well- being positively. 
In particular, some participants described how this made 
them feel like it was their fault if they relapsed or felt they 
had to resume ADMs: ‘I feel sad and disappointed that 
stopping [ADMs] made me feel low again. […] It makes 
me feel I'm not right in the head compared to others. I 
also feel annoyed with myself for not utilising MBCT skills 
learnt better’ (2123; Written feedback, Discontinued and 
resumed). Furthermore, a substantial number of partici-
pants expressed the challenge of finding the time, moti-
vation or self- discipline to keep up a regular mindfulness 
practice outside of the group sessions. Therefore, the 
sense of control did not always feel stable, as it was contin-
gent on finding time to practice and ‘do it religiously, 
otherwise I would be fearful of it not being enough’ 
(2102; Written feedback, Never tapered or discontinued). Some 
were disappointed when they realised that psychological 
therapy was not an ‘all- encompassing cure’ (1222, Inter-
view, Discontinued and resumed) and would involve an active 
and ongoing process of engagement with the techniques 
learned.
Acceptance
This over- arching theme describes people’s feelings of 
acceptance towards their history of recurrent depression 
and ongoing need to manage risk of relapse and recur-
rence. People reported feeling a sense of shame around 
long- term reliance on ADMs before the trial, feeling it 
labelled them as an ill person even if feeling well. After 
the trial, people described an increased sense of accep-
tance regarding their vulnerability to depression and an 
increased motivation to engage in self- care to support 
their recovery. This self- management included either 
ADMs and/or the psychological techniques for different 
people. This theme comprises three sub- themes.
Resolving shame
Many participants recalled that before the trial they had 
felt ‘inadequate’ or unable to cope with life compared 
with other people because of their recurrent depression 
treating it as a ‘guilty secret’ (1123; Interview, Tapered but 
never discontinued). Taking ADMs had helped some people 
by reducing the symptoms and allowing them to return 
to feeling like a ‘normal contributing person in society’ 
(2200; Interview, Tapered but never discontinued). However, 
others said that having to take ADMs on an ongoing basis 
gave them an underlying feeling that they were still ‘not a 
well person’ (2102; Interviews, Never tapered or discontinued), 
even when the symptoms of depression were absent. For 
these reasons, some people recalled how before the trial, 
they found it difficult to name their depression, and 
‘couldn’t even or wouldn’t even admit to that’ (1031, Inter-
view, Never tapered or discontinued). Through MBCT- TS, 
some participants described how they felt able to name 
their condition as depression for the first time. They 
discussed how meeting other people in the programme 
had made them realise that depression was not a negative 
aspect of their own self- identity, but an aspect of human 
experience: ‘You realise it is part of the human condition 
rather than you’ (1128; Interview, Never tapered or discon-
tinued), and it ‘confirmed that I am a human, worthwhile 
person’ (2176; Written feedback, Discontinued and resumed). 
This led to increased feelings of acceptance towards 
depression, because participants experienced a shift away 
from viewing themselves as abnormal, to seeing depres-
sion as a more acceptable response to life’s difficulties: 
‘Giving yourself credit […] ‘cause at the end of the day 
[…] our human brain is quite a complex thing, isn’t it? 
[…] There’s nothing wrong in feeling like it’ (2140; Inter-
view, Discontinued and resumed).
Self-care
Participants described how developing more acceptance 
towards their condition improved their attitudes towards 
self- care. They said that accepting their vulnerability 
to depression allowed them to ‘look at solutions’ and 
that they finally had ‘consent to actually do something 
about it’ (1031, Interview, Never tapered or discontinued). 
People described how they increasingly accepted that 
they needed to take care of themselves, and explained 
how the programme had taught them legitimate ways to 
do this such as using mindfulness practices: ‘Previously 
was a mindset […] that I wasn’t allowed to help myself 
feel better. […] Whereas this felt a way that I could do 
it without mollycoddling myself’ (1031, Interview, Never 
tapered or discontinued). Participants also described how 
the programme had reframed self- care not as something 
‘fluffy’, but as ‘practical’ and a necessary part of their 
ongoing recovery: ‘It doesn’t make you any less male of 
course. [Chuckles] Or any less powerful’ (1203, Interview, 
Discontinued). In some cases, this new attitude towards self- 
care caused a shift such that people felt more acceptance 
towards taking ADMs: ‘I don't feel any more when I take 
my pill every morning that there's something wrong with 
me’ as they recognised it was important to do ‘everything 
in my power to help myself’ (1177, Interview, Tapered but 
never discontinued). Some participants also described how 
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originally they had taken ADMs unwillingly, whereas after 
MBCT- TS they decided to take ADMs as an act of effective 
self- management: ‘I used to hate taking them [ADMs] I 
accept [now] it’s all about looking after yourself isn't it?’ 
(3103; Interview, Discontinued and resumed).
Perspectives on relapse
One dimension of acceptance was people’s perspectives 
on mood fluctuations and relapse itself. Some people 
favoured ADMs as an approach to relapse prevention, 
because it guaranteed them stability in their mood. For 
instance, when Greta experienced a deterioration in 
mood, she interpreted this as a sign that the MBCT- TS 
programme had been a ‘failure’ and she resumed 
taking ADMs (see box 1). However, this was not always 
the case, and many people described how participating 
in MBCT- TS changed their attitude towards relapse/
recurrence. In particular, some people felt more able to 
accept mood fluctuations and even periods of depression. 
They described approaching them in a different way, 
‘thinking it was a phase that one was going through and 
sort of accepting, okay this is how you're feeling today’ 
(1159; Interview, Discontinued and resumed). Some people 
reported that they no longer wanted to ‘blank out their 
negative emotions’, and so did not resume ADMs, even 
if they relapsed: ‘it’s definitely helped me to realise that 
they [negative emotions] are a part of me as well’ (4057, 
Interview, Discontinued).
Quality of life
People reflected on the ways in which treatment choices 
influenced their quality of life, specifically moving them 
from a place of coping, to a position where they could 
enjoy and appreciate their lives. This theme comprises 
two sub- themes.
Experiencing emotions more fully
On reflecting on their experiences with ADMs, some 
participants said that while ADMs lessened their low 
mood, at the same time they ‘dampen all other emotions’, 
for instance, they could not feel ‘blissfully happy, couldn’t 
get angry, and in hindsight feel I was sedated’ (4057, 
Written feedback, Discontinued). In the context of depres-
sion, some people viewed this numbing effect as helpful, 
and reflected that while ADMs ‘take away the euphoria 
that you would get when you've done something really, 
really, really good’, this was ‘a small price to pay really for 
not having the really dark times’ (2200; Interviews, Tapered 
but never discontinued). However, many people thought 
that this had negatively affected their quality of life, espe-
cially in cases where they found it hard to experience 
positive emotions. This appeared to influence people’s 
decision to taper or discontinue ADMs, because they said 
that restoring their emotional range was an important 
part of their long- term vision of recovery: both George 
and Claire described this as a key motivator to discon-
tinue their ADMs (see box 1). Indeed, people described 
how their emotional capacity increased after coming off 
ADMs: ‘I am more alive: my emotions aren't “levelled out” 
anymore. I can be happy, sad, angry or calm instead of 
just bland’ (4057, Written feedback, Discontinued). Despite 
this, some people found it a bit of a ‘shock’ at first, when 
faced with ‘very extreme emotions and feelings’ again 
(1212; Feedback booklets, Discontinued). Therefore, people 
found it helpful that the programme taught them tech-
niques to help manage this transition: ‘I definitely used 
mindfulness during coming off the tablets to […] be 
aware what’s going on inside and […] calm myself down, 
to have those little islands of tranquillity’ (4057, Written 
feedback, Discontinued). On the other hand, some partic-
ipants said that despite not tapering or discontinuing 
ADMs, the programme had helped them to cultivate 
more positive emotions, and appeared to increase their 
quality of life on ADMs: ‘I suppose the mindfulness in 
that respect has helped because […] by slowing yourself 
down you can […] capture some of that […] joy of life 
that possibly I would have lost’ (2200; Interviews, Tapered 
but never discontinued).
From coping to enjoying life
Many people reflected that in their recovery journey they 
had been grateful for the periods of time where they were 
simply able to function. However, some participants said 
that the programme had helped them to move beyond 
that mind- set, and to develop more well- being and appre-
ciate life: ‘What has changed? I think my outlook on life, 
I love life, I really do […] People said to me […] before 
you used to skulk into the room, now you light up the 
room. […] I do enjoy life now, where I didn’t before’ 
(2016, Interview, Discontinued). They valued the fact that 
the programme had an active focus on positive func-
tioning, and encouraged them to take part in activities 
that brought happiness and joy into their life. Partici-
pants described this as an active process, facilitated by a 
sense of having more control and autonomy over making 
positive decisions in their life: ‘I rearranged my life so 
that the things I do now are things that I enjoy and want 
to do’ (1203, Interviews, Discontinued); ‘I am now making 
bigger future plans to make my life better and intro-
ducing new ventures’ (1031, Written feedback, Never tapered 
or discontinued).
ADM tapering/discontinuation
The study’s focus included people’s experiences of 
tapering and discontinuing ADMs in the context of the 
MBCT- TS programme. This theme describes participants’ 
views of what helped or hindered the process of discon-
tinuation. It comprises two sub- themes.
Timing
Reflecting on the right time to engage with different 
treatments, many participants felt that ADMs were 
helpful when they first became depressed: ‘they got me 
out of my initial depression so that I could cope more 
with just everyday life’ (4007, Interview, Never tapered or 
discontinued). However, many did not envisage being on 
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ADMs indefinitely, and they described an increasing need 
for insight and self- management of depression as time 
went on. They thought that the MBCT- TS techniques 
required more effort, but supported a longer- term vision 
of recovery, to ‘recognise what makes you depressed and 
to give you a way to cope with your depression throughout 
your life for the long- term, and a way that you can come 
off [ADMs]’ (4007, Interview, Never reduced or discontinued). 
As illustrated by this quotation, some participants viewed 
the MBCT- TS skills as part of a longer- term solution to 
ADM discontinuation, which extended beyond the 2- year 
follow- up period. Some participants reflected on how they 
thought the two treatments could be used in combination 
to support people at different parts of their journey, from 
depression through to recovery: ‘I think you need that 
initial boost of antidepressant to perhaps get you back 
into a more rational level, and then once you’ve reached 
that, then bring in the MBCT, until you get back then 
you know, be weaned off. I can see that working very well 
really’ (1108, Interview, Never reduced or discontinued).
Participants discussed the pace at which they tapered 
ADMs, and how they perceived this to have influenced 
their outcomes. Some people who were worried about 
coming off ADMs shared that they exercised caution, 
testing out the psychological techniques for a set period 
and tapering slowly. They said this was helpful as it gave 
them time to learn to use the psychological techniques 
before giving up the support of their ADMs, ‘by doing it 
slowly, you are learning those skills and you are finding 
out how you can use it. [Then] you can start dropping it 
[ADMs] at your own pace’ (1075; Interviews, Discontinued). 
In comparison, those who were keen to come off ADMs 
and were less fearful of the consequences described 
tapering more quickly. Although the programme had 
included explicit guidance to taper gradually, partic-
ipants’ reports suggested that many people had gone 
against this advice, and were looking for a ‘quick fix’ 
to ‘get off the pills as quick as possible’ (2131, Interview, 
Tapered but never discontinued). However, on reflection 
many people thought, ‘perhaps that wasn't the answer 
perhaps the thing ought to be graded on over a longer 
period’ (2131, Interviews, Tapered but never discontinued). 
Some of these participants reflected that in retrospect 
they should have been more cautious, and tapering too 
quickly had led to poorer outcomes: ‘I reduced my tablets 
too quick and paid the price by having to get straight back 
to the full dose’ (2016, Interview; Written feedback, Discon-
tinued). However, some people, like Claire, who did not 
successfully discontinue on their first attempt reported 
how they had then tried again, tapering more gradually 
and with more success (see box 1).
Managing withdrawal effects
People said that the programme had helped them to 
cope with withdrawal effects during and after tapering/
discontinuing ADMs. They described how the group and 
the meditation techniques provided ongoing support to 
manage this period: ‘I used meditation techniques […] 
tried to treat myself with pleasurable experiences and told 
myself that this would pass over. […] I had a network of 
fellow participants and a trustworthy instructor. All of this 
put me in a position of confidence that it would work this 
time’ (4057, Written feedback, Discontinued). In addition, 
people said that they were better able to differentiate the 
side effects of ADM withdrawal from a depressive relapse. 
For instance, Mandy said that in the past, withdrawal 
effects had been the biggest hindrance to tapering ADMs, 
because she had always mistaken them for a depressive 
relapse and resumed her medication. On the programme, 
she learned how to differentiate between these effects 
and ‘real relapses’, and said that tapering was relatively 
‘easy’ this time around (see box 1). Indeed, some people 
recalled attempting to discontinue ADMs before the trial 
and their withdrawal symptoms being ‘misdiagnosed’ ‘as 
recurring depression’, whereas this time they ‘knew what 
was coming’ (4057, Written feedback, Discontinued).
Interactions with GP
Participants’ described their interactions with their GPs 
as being important in their recovery, in both positive and 
negative ways. This theme comprises two sub- themes.
Presence and support
Participants described having a GP who was easy to access 
throughout the process of discontinuation as supportive: 
‘Knowing that I could ring the doctor and say, “I need 
to make an appointment, I need to come and see you.” 
There was always that net underneath me to catch me 
if I was falling and I couldn't stop it’ (2090, Interview, 
Discontinued), whereas some participants said they found 
it ‘very difficult’ to access their GPs, and so felt ‘unsup-
ported’ (1123, Written feedback, Tapered but never discon-
tinued). Participants reported a more positive attitude to 
the programme if their GP had endorsed it, and some 
said they had only been convinced to take part in the trial 
because their GPs said they had themselves done a mind-
fulness course. When GPs encouraged their patients to use 
the mindfulness practices, this appeared to be associated 
with better engagement and subsequent success in ADM 
tapering and discontinuation: ‘I did reach a stage where I 
went to see my G.P. as the depression was returning. […] 
We decided that I should try the exercises before trying 
pills. I did not need to go back on them yet […] My GP is 
a great help’ (2090, Written feedback, Discontinued).
Following advice
Participants differed in the extent to which they sought 
and followed the advice of their GPs. For instance, some 
participants described that they remained on their ADMs 
at their GP’s suggestion: ‘My GP would not allow me to 
come off my antidepressant or reduce it because I had 
been on them so long term. [I am] relieved but also a 
bit disappointed’ (1108; Written feedback, Never tapered or 
discontinued). This adherence to medical advice seemed 
to be greater for participants who had more concerns 
about discontinuation. For instance, Claire, who relapsed 
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the first time that she had attempted tapering and discon-
tinuation, was much more receptive to her GP’s advice the 
second time around, because she was afraid of relapsing 
again (see box 1). On the other hand, where people were 
confident that they had learned the skills to self- manage 
their depression without ADMs, they more often reported 
that they could manage the process independently, and 
placed less value on their GP’s advice: ‘I went along to 
the doctors because I was polite to ask him if I could stop 
taking it. And he said, “Well yeah maybe in a few months 
time you can taper it- ease it off a bit.” But really I had 
decided (laughs) I was going to stop. So I was just there 
out of politeness’ (1203; Interview, Discontinued).
DISCuSSION
Statement of principal findings
This study explored the recovery journeys of people 
with recurrent depression who followed a programme 
(MBCT- TS), designed to teach psychological skills to 
prevent depressive relapse while providing advice to 
encourage tapering and discontinuation of mainte-
nance ADMs.13 Thematic analysis suggested people have 
unique recovery journeys, but tend to be characterised 
by six common themes. Five illustrative stories are repre-
sented in case studies (box 1). The over- arching themes 
in participants’ accounts were: beliefs about the causes of 
depression, personal agency, acceptance, quality of life, 
ADM tapering/discontinuation and interactions with 
GP (table 2). Together, these findings have the potential 
to facilitate discussions between clinicians and patients 
about the depression recovery journey. The findings also 
provide a starting point for more research into which 
treatments for recurrent depression, or combination of 
treatments, work best for whom and when.
Strengths and weaknesses of this study
This study had a number of methodological strengths. We 
had a relatively large sample and purposively sampled the 
population for whom this research is relevant—people 
with a history of recurrent depression, stable on mainte-
nance ADMs who were open to both a psychological and 
pharmacological approach to recovery. The study’s time 
frame enabled participants to reflect on their journey 
with MBCT- TS and ADMs over 2 years. To support partic-
ipants’ recollection we developed prompts about the 
course of their depression and ADM use over the 2- year 
period based on information we had collected as part of 
the parent RCT.
Alongside these strengths, it is important to consider 
the context within which the study took place and its 
implications for interpretation of the findings. First, the 
trial was pragmatic in that it recruited participants from 
a particular population.16 However, it did not include 
people either unwilling to consider a psychological 
therapy or unwilling to consider tapering/discontinuing 
their medication. Second, the parent trial included moni-
toring participants’ use of ADM, and if people following 
MBCT- TS were not tapering/discontinuing they were 
invited to discuss this with their GPs. Some participants 
reported feeling pressured to discontinue ADMs and it 
is reasonable to assume that some participants may have 
made different decisions in a more naturalistic setting. 
Third, our purposive sampling means this study does 
not speak to a larger population of people with a history 
of depression who are not interested in a psychological 
approach and tapering/discontinuing their ADMs, or 
indeed prefer not to use ADM. Fourth, the questions 
in our feedback booklets and interviews had a partic-
ular framing, and it is possible that if the questions 
were framed differently the answers too may have been 
different. Finally, for pragmatic reasons we did not ask 
participants’ feedback on the themes as is sometimes 
done in qualitative research.
Implications of our findings
Several RCTs have demonstrated that psychological ther-
apies such as CBT and MBCT can support ADM discon-
tinuation,8–10 but to our knowledge, no qualitative studies 
have examined people’s experiences of this process. 
This study adds to the body of literature suggesting that 
people’s journey involves choices among different treat-
ments, shaped by their prior beliefs, expectations, expe-
riences and interactions with their GPs. In both MBCT 
and CBT people learn new skills to manage depressive 
symptoms, gaining new perspectives drawn from both 
the psychological model and peer- to- peer learning, and 
develop an increased sense of agency concerning ADM 
discontinuation.11 20 21 In this study participants described 
learning attitudes towards self- care that were participa-
tory and empowering, which facilitated a sense of agency 
around ADM use, tapering and discontinuation. On the 
other hand, some people’s biological beliefs about depres-
sion, positive experiences of ADM, and/or negative expe-
riences of psychological therapies meant they were happy 
to use ADM as their primary approach to recovery.
People also emphasised the importance of a GP who is 
accessible and able to provide support that is collabora-
tive, individualised and empowering, with careful moni-
toring over time. Moreover, they described how GPs had 
powerfully shared their models of depression, expecta-
tions of treatment and treatment choices. The implication 
for GPs is to provide accessible, collaborative, individual-
ised and empowering care. Moreover GPs should provide 
people with explanatory models of depression that are 
bio- psycho- social alongside appropriate pharmacological 
and psychological treatment choices. Our findings along-
side others21–23 also suggest GPs should not offer an overly 
simplistic biological model, for example, ‘your serotonin 
levels are low’, followed by a (repeat) prescription of 
ADM.
ADMs are currently the mainstay treatment approach 
to recurrent depression. Kendrick has argued that many 
people remain on ADMs without clinical need and could 
benefit from support and guidance on how to discontinue, 
especially regarding how to deal with initial withdrawal 
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symptoms.23 Our findings underscore this. Moreover, 
participants spoke of the importance of feeling that they 
had acquired from alternative skills in MBCT- TS to support 
their recovery generally by being able to manage their 
depression, but also ADM tapering and discontinuation 
specifically. For example, where life circumstances were 
challenging some people felt that the time was not right 
for them to discontinue ADMs; they made an informed 
decision to continue with their medication. Even so, the 
majority of participants who remained on ADMs reported 
that the MBCT- TS treatment had increased their quality 
of life on ADMs, and improved their confidence in future 
discontinuation when circumstances were more favour-
able. Our analysis also outlines participants’ views on the 
appropriate timing of different treatments, which provide 
ideas for when it might be an appropriate time to initiate 
conversations about ADM and MBCT treatment choices.
People described how their expectations of both MBCT 
and ADM influenced their treatment choices. Although 
it is widely assumed that positive expectations predict 
greater benefit in psychological therapy, in our sample 
both unrealistically positive expectations (eg, expecting 
MBCT- TS to be an ‘all- encompassing cure- all’) and very 
negative expectations (having ‘no intellectual confidence 
in the process’) appeared to act as a barrier to engage-
ment. These findings are consistent with those of Malpass 
et al7 and suggest that openly discussing expectations at 
key junctures is likely to be key in preventing disappoint-
ment or disengagement from what is an effortful process 
of change. Likewise, in line with Maund et al’s findings,6 
people’s causal models of depression also appeared 
to influence their expectations and engagement with 
psychological therapy. Moreover, they were subject to 
change during and beyond the therapy process, as their 
experiences either confirmed or disconfirmed their 
expectations and working model of depression and its 
treatment. People who suffer from depression frequently 
endorse biomedical explanations,24 and this was evident 
in our sample. A number of people reported that they 
derived these models from discussions with their GPs as 
a rationale for taking ADMs. Previous research suggests 
that conceiving depression as a biomedical illness can 
absolve people of personal responsibility and thus chal-
lenge stereotypes of depression resulting from personal 
weakness.7 However, our findings suggest that strongly 
held biomedical beliefs appeared to increase feelings 
of dependency on ADMs, and contribute to negative 
expectations and lack of engagement with psychological 
therapy. On the other hand, while learning a psycho-
logical model of depression empowered people towards 
more self- management of depression and feelings of 
mastery over their emotional well- being, in some cases, 
when people developed a psychological understanding 
and then went on to relapse, they blamed themselves. 
In some cases, practical life circumstances also made it 
very difficult for people to engage in an approach that 
required time and effort. Together, this suggests that 
polarised beliefs about the causes of depression can 
either compromise self- efficacy or promote self- blame. 
Many participants found it helpful to bridge biomedical 
and psychological theories, with parallels to a ‘biopsycho-
social’ framework,25 rather than viewing separate theories 
as competing, which seemed to foster more flexibility, 
self- compassion and open- mindedness towards trying 
different treatment options at different times in their 
journey of managing recurrent depression. This high-
lights the importance of recognising that a myriad of 
factors, including genetic vulnerability and challenging 
social circumstances, can influence depression.
People sometimes describe ADMs as sedating or 
numbing.26 In these interviews participants said this could 
influence their decision- making about ADM use. For 
example, in the instance of numbing, some people viewed 
this as helpful as it reduced their feelings of depression, 
whereas other people said that ADMs numbed all of their 
emotions, including positive feelings, and this contrib-
uted towards a desire to discontinue them. These findings 
add to ongoing discussion about the psychoactive effects 
of ADMs, including their potential benefits and costs, 
how these effects impact people’s experience of recovery 
from depression and how participating in psychological 
therapy can interact with these experiences.
Finally, descriptions of the role of the GP in supporting 
ADM discontinuation varied markedly, and this appeared 
to result both from differences between patients in their 
preferred level of guidance and support, and the avail-
ability of their GPs to provide this. For example, some 
people adhered to their GP’s advice although this was in 
conflict with their own desired approach, some described 
informing their GP of their intentions as an act of cour-
tesy, and some did not involve their GP at all. In some of 
these latter cases, participants felt that they would have 
benefited from more support, but their GP, for a range of 
reasons, was unable to provide this. People also described 
needing more understanding and support over time as 
they took more responsibility for managing their depres-
sion. This is in line with findings from Malpass et al,7 who 
suggested that people vary in the extent to which they 
want to be involved in treatment decision- making, and 
their preferences for involvement are dynamic, not static. 
Archer has described different ‘modes of reflexivity’ 
noting the varying degrees to which people act autono-
mously or rely on endorsement from others.27 Moreover, 
recovery meant different things to different people, and 
overall, the outcome most important to patients appeared 
to be their day- to- day functioning and quality of life. It is 
likely that when GPs are able to recognise their patients’ 
preferred mode of engagement, and complex, dynamic 
views of recovery and adapt their approach accordingly, 
this will facilitate patient–GP consultations about ADM 
and psychological therapies treatment choices.
unanswered questions and future research
This work adds to the emerging literature on people’s 
experiences of recovery from depression with ADM 
and psychological therapies. Applied research asking 
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how patients and health professionals communicate 
about their respective models of depression, and under-
stand how this affects treatment decisions, compliance, 
outcomes and a broader conceptualisation of recovery 
would be valuable. Extending this to the broader popu-
lation of people who suffer depression would not only 
provide an interesting and important alternate perspec-
tive but also will be important to consider with respect to 
recovery journeys and treatment choices.
Our work took a qualitative approach. An obvious next 
question asks how these process variables affect outcomes. 
That is to say, what works for who, how, when, to affect 
treatment outcomes? Finally, such research should priori-
tise the outcome that is most meaningful to patients: their 
day- to- day functioning and quality of life.
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